Ibritumomab tiuxetan
- Generic Name
- Ibritumomab tiuxetan
- Brand Names
- Zevalin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 206181-63-7
- Unique Ingredient Identifier
- 4Q52C550XK
- Background
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
- Indication
For treatment of non-Hodgkin's lymphoma
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 149
- Registration Number
- NCT00662948
- Locations
- 🇪🇸
Hospital Dr Pesset, Valencia, Spain
🇪🇸Hospital La Paz, Madrid, Spain
🇪🇸Hospital Doce de Octubre, Madrid, Spain
Zevalin-beam for Aggressive Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00491491
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇩🇪Georg-August Universität, Göttingen, Germany
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 18
- Registration Number
- NCT00453102
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT00392691
- Locations
- 🇨🇭
Saint Claraspital AG, Basel, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭Kantonsspital Liestal, Bern, Switzerland
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 18
- Registration Number
- NCT00372905
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00319332
- Locations
- 🇺🇸
GSK Clinical Trials Call Center, Tacoma, Washington, United States
🇺🇸GSK Clinical Trial Call Center, Seattle, Washington, United States
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193440
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.